| Aug 7 |
Novartis gets FDA approval for Fabhalta in IgAN patients
|
| Aug 6 |
Novartis AG (NVS): The Best Organ Transplant and Diagnosis Stock According to Street Analysts?
|
| Aug 6 |
Pipeline Moves: Novartis terminates Phase II ALS trial after benefit-risk worry
|
| Aug 5 |
Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims
|
| Aug 2 |
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
|
| Aug 2 |
Q2 2024 Ionis Pharmaceuticals Inc Earnings Call
|
| Aug 1 |
Novartis sues FDA for approving Entresto generic
|
| Jul 30 |
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Jul 30 |
FDA grants priority review for Novartis’ leukaemia treatment
|
| Jul 29 |
Novartis' Scemblix granted FDA Priority Review status for front-line CML
|
